These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 26554252)

  • 1. CYP2C9 Genetic Polymorphism is a Potential Predictive Marker for the Efficacy of Rosuvastatin Therapy.
    Lin J; Zhang Y; Zhou H; Wang X; Wang W
    Clin Lab; 2015; 61(9):1317-24. PubMed ID: 26554252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between genetic polymorphism of drug transporters and the efficacy of Rosuvastatin, atorvastatin and simvastatin in patients with hyperlipidemia.
    Sivkov A; Chernus N; Gorenkov R; Sivkov S; Sivkova S; Savina T
    Lipids Health Dis; 2021 Nov; 20(1):157. PubMed ID: 34749751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymorphisms in apolipoprotein E and apolipoprotein A-V do not influence the lipid response to rosuvastatin but are associated with baseline lipid levels in Chinese patients with hyperlipidemia.
    Hu M; Mak VW; Tomlinson B
    J Clin Lipidol; 2012; 6(6):585-92. PubMed ID: 23312054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of association between SLCO1B1 polymorphism and the lipid-lowering effects of atorvastatin and simvastatin in Chinese individuals.
    Fu Q; Li YP; Gao Y; Yang SH; Lu PQ; Jia M; Zhang LR
    Eur J Clin Pharmacol; 2013 Jun; 69(6):1269-74. PubMed ID: 23263738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endothelial lipase genetic polymorphisms and the lipid-lowering response in patients with coronary artery disease on rosuvastatin.
    Cai G; Zhang B; Shi G; Weng W; Yang L; Xue S
    Lipids Health Dis; 2016 Sep; 15(1):148. PubMed ID: 27600285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Periodic rosuvastatin or atorvastatin dosing arrays (PRADA): patient-centered practice.
    Christou T; Omar HR; Dimitrov R
    Drugs R D; 2014 Dec; 14(4):221-5. PubMed ID: 25160776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of rosuvastatin in treatment of dyslipidemia.
    McKenney JM
    Am J Health Syst Pharm; 2005 May; 62(10):1033-47. PubMed ID: 15901588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Food Effect on Rosuvastatin Disposition and Low-Density Lipoprotein Cholesterol.
    McLean CC; Teft WA; Morse BL; Gryn SE; Hegele RA; Kim RB
    Clin Pharmacol Ther; 2018 Sep; 104(3):525-533. PubMed ID: 29218707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ile118Val genetic polymorphism of CYP3A4 and its effects on lipid-lowering efficacy of simvastatin in Chinese hyperlipidemic patients.
    Wang A; Yu BN; Luo CH; Tan ZR; Zhou G; Wang LS; Zhang W; Li Z; Liu J; Zhou HH
    Eur J Clin Pharmacol; 2005 Feb; 60(12):843-8. PubMed ID: 15650881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients.
    Lee HK; Hu M; Lui SSh; Ho CS; Wong CK; Tomlinson B
    Pharmacogenomics; 2013 Aug; 14(11):1283-94. PubMed ID: 23930675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical evaluation of rosuvastatin in heart transplant patients with hypercholesterolemia and therapeutic failure of other statin regimens: short-term and long-term efficacy and safety results.
    Barge-Caballero G; Barge-Caballero E; Marzoa-Rivas R; Paniagua-Martín MJ; Barrio-Rodríguez A; Naya-Leira C; Blanco-Canosa P; Grille-Cancela Z; Vázquez-Rodríguez JM; Crespo-Leiro MG
    Transpl Int; 2015 Sep; 28(9):1034-41. PubMed ID: 25864881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study.
    Bailey KM; Romaine SP; Jackson BM; Farrin AJ; Efthymiou M; Barth JH; Copeland J; McCormack T; Whitehead A; Flather MD; Samani NJ; Nixon J; Hall AS; Balmforth AJ;
    Circ Cardiovasc Genet; 2010 Jun; 3(3):276-85. PubMed ID: 20207952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The lipid-lowering efficacy of rosuvastatin is associated with variations in SLCO1B1: a 12-month prospective cohort study.
    Zakria M; Hussain A; Ahmad N; Ahmed N; Rauf MA; Siraj S
    Eur Rev Med Pharmacol Sci; 2023 May; 27(10):4708-4717. PubMed ID: 37259755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE; Feely J; Sigurdsson EL;
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Starting with rosuvastatin in primary hyperlipidemia--Is there more than lipid lowering?
    Milionis HJ; Gazi IF; Filippatos TD; Tzovaras V; Chasiotis G; Goudevenos J; Seferiadis K; Elisaf MS
    Angiology; 2005; 56(5):585-92. PubMed ID: 16193198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rosuvastatin alone or with extended-release niacin: a new therapeutic option for patients with combined hyperlipidemia.
    Capuzzi DM; Morgan JM; Carey CM; Intenzo C; Tulenko T; Kearney D; Walker K; Cressman MD
    Prev Cardiol; 2004; 7(4):176-81. PubMed ID: 15539964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interactions between CYP3A5*3 and POR*28 polymorphisms and lipid lowering response with atorvastatin.
    Wei KK; Zhang LR
    Clin Drug Investig; 2015 Sep; 35(9):583-91. PubMed ID: 26293521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies.
    Glueck CJ; Aregawi D; Agloria M; Khalil Q; Winiarska M; Munjal J; Gogineni S; Wang P
    Clin Ther; 2006 Jun; 28(6):933-42. PubMed ID: 16860175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Effect of Genetic Polymorphisms in SLCO2B1 on the Lipid-Lowering Efficacy of Rosuvastatin in Healthy Adults with Elevated Low-Density Lipoprotein.
    Kim TE; Shin D; Gu N; Jung BH; Kim J; Cho YM; Yu KS; Cho JY
    Basic Clin Pharmacol Toxicol; 2017 Sep; 121(3):195-201. PubMed ID: 28627804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of rosuvastatin in Taiwanese patients.
    Chiang CE; Huang SS; Sung SH
    J Chin Med Assoc; 2008 Mar; 71(3):113-8. PubMed ID: 18364261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.